300406 九强生物
已收盘 08-23 15:00:00
资讯
新帖
简况
九强生物(300406)2024年中报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 08-24 06:16
九强生物(300406)2024年中报简析:营收净利润同比双双增长,盈利能力上升
九强生物(300406)6月30日股东户数1.56万户,较上期增加18%
证券之星 · 08-23 17:10
九强生物(300406)6月30日股东户数1.56万户,较上期增加18%
图解九强生物中报:第二季度单季净利润同比减0.63%
证券之星 · 08-23 01:30
图解九强生物中报:第二季度单季净利润同比减0.63%
九强生物(300406.SZ)发布上半年业绩,净利润2.5亿元,同比增长3.64%
智通财经 · 08-22 19:42
九强生物(300406.SZ)发布上半年业绩,净利润2.5亿元,同比增长3.64%
九强生物最新公告:全资子公司迈新拟288.50万元收购Lumatas股份
证券之星 · 08-22 18:41
九强生物最新公告:全资子公司迈新拟288.50万元收购Lumatas股份
九强生物最新公告:2024年上半年净利润2.50亿元 同比增长3.64%
证券之星 · 08-22 18:39
九强生物最新公告:2024年上半年净利润2.50亿元 同比增长3.64%
7月31日九强生物涨5.25%,农银医疗保健股票基金重仓该股
证券之星 · 07-31
7月31日九强生物涨5.25%,农银医疗保健股票基金重仓该股
九强生物涨5.25%,中泰证券二个月前给出“买入”评级
证券之星 · 07-31
九强生物涨5.25%,中泰证券二个月前给出“买入”评级
九强生物(300406)7月29日主力资金净卖出492.87万元
证券之星 · 07-30
九强生物(300406)7月29日主力资金净卖出492.87万元
九强生物(300406)29.12万股限售股将于7月30日解禁,占总股本0.05%
证券之星 · 07-30
九强生物(300406)29.12万股限售股将于7月30日解禁,占总股本0.05%
7月23日九强生物创60日新低,农银医疗保健股票基金重仓该股
证券之星 · 07-23
7月23日九强生物创60日新低,农银医疗保健股票基金重仓该股
九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份
智通财经 · 07-22
九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份
【九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份】智通财经APP讯,九强生物(300406.SZ)发布公告,截至2024年7月19日,公司本次回购股份的实施期限届满,公司累计通过股份回购专用账户以集中竞价方式实施回购公司股份482.
智通财经 · 07-22
【九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份】智通财经APP讯,九强生物(300406.SZ)发布公告,截至2024年7月19日,公司本次回购股份的实施期限届满,公司累计通过股份回购专用账户以集中竞价方式实施回购公司股份482.
九强生物获得发明专利授权:“丙戊酸衍生物在免疫检测中的用途”
证券之星 · 07-18
九强生物获得发明专利授权:“丙戊酸衍生物在免疫检测中的用途”
九强生物(300406)109.87万股限售股将于7月12日解禁,占总股本0.19%
证券之星 · 07-12
九强生物(300406)109.87万股限售股将于7月12日解禁,占总股本0.19%
【九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元】智通财经APP讯,九强生物(300406.
智通财经 · 07-01
【九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元】智通财经APP讯,九强生物(300406.
九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元
智通财经 · 07-01
九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元
【中泰证券:关注Q2业绩超预期 把握医药底部资产】智通财经APP获悉,中泰证券发布研报称,展望下半年,行业基本面有望从24Q3开始改善,低基数下业绩增速有望逐季回升,政策层面创新药支持政策、医疗反腐等均有望边际向好,医药板块有望迎来一波强势反弹,建议当下提前布局底部有弹性的资产。
智通财经 · 07-01
【中泰证券:关注Q2业绩超预期 把握医药底部资产】智通财经APP获悉,中泰证券发布研报称,展望下半年,行业基本面有望从24Q3开始改善,低基数下业绩增速有望逐季回升,政策层面创新药支持政策、医疗反腐等均有望边际向好,医药板块有望迎来一波强势反弹,建议当下提前布局底部有弹性的资产。
九强生物(300406)6月27日主力资金净卖出771.68万元
证券之星 · 06-28
九强生物(300406)6月27日主力资金净卖出771.68万元
九强生物(300406)6月26日主力资金净卖出322.62万元
证券之星 · 06-27
九强生物(300406)6月26日主力资金净卖出322.62万元
加载更多
公司概况
公司名称:
北京九强生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2014-10-30
主营业务:
北京九强生物技术股份有限公司主营业务是生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、生产和销售。主要产品包括胱抑素C、同型半胱氨酸、胆汁酸(TBA)、载脂蛋白A1、载脂蛋白B、小而密低密度脂蛋白胆固醇、肌酸激酶同工酶(mass法)等生化诊断试剂。2023年2月22日,2022年(第29批)新认定国家企业技术中心名单及全部国家企业技术中心名单公布,公司成功入选,荣获“国家企业技术中心”认定。
发行价格:
14.32
{"stockData":{"symbol":"300406","market":"SZ","secType":"STK","nameCN":"九强生物","latestPrice":12.91,"timestamp":1724396634000,"preClose":12.9,"halted":0,"volume":3392462,"delay":0,"floatShares":423000000,"shares":588000000,"eps":0.9051,"marketStatus":"已收盘","marketStatusCode":5,"change":0.01,"latestTime":"08-23 15:00:00","open":12.87,"high":12.98,"low":12.74,"amount":43603900,"amplitude":0.0186,"askPrice":12.92,"askSize":10,"bidPrice":12.91,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.9051,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":12.9,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":14.19,"lowLimit":11.61,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":588446310,"pbRate":2.07,"roa":"--","roe":"6.53%","epsLYR":0.9,"committee":0.028929,"marketValue":7597000000,"floatMarketCap":5464000000,"peRate":14.263617,"changeRate":0.0008,"turnoverRate":0.008,"status":0},"requestUrl":"/m/hq/s/300406","defaultTab":"news","newsList":[{"id":"2461522963","title":"九强生物(300406)2024年中报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2461522963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461522963?lang=zh_cn&edition=full","pubTime":"2024-08-24 06:16","pubTimestamp":1724451370,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期九强生物发布2024年中报。截至本报告期末,公司营业总收入8.22亿元,同比上升0.66%,归母净利润2.5亿元,同比上升3.64%。本报告期九强生物盈利能力上升,毛利率同比增幅3.69%,净利率同比增幅3.6%。经营活动产生的现金流量净额变动幅度为32.8%,原因:销售商品收到的现金较去年同期增加。筹资活动产生的现金流量净额变动幅度为-186.14%,原因:分配现金股利较去年同期增加、借款金额低于去年同期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082400005790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"gpt_icon":0},{"id":"2461433552","title":"九强生物(300406)6月30日股东户数1.56万户,较上期增加18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461433552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461433552?lang=zh_cn&edition=full","pubTime":"2024-08-23 17:10","pubTimestamp":1724404238,"startTime":"0","endTime":"0","summary":"证券之星消息,近日九强生物披露,截至2024年6月30日公司股东户数为1.56万户,较3月31日增加2374.0户,增幅为18.0%。在医疗器械行业个股中,九强生物股东户数低于行业平均水平,截至6月30日,医疗器械行业平均股东户数为2.05万户。九强生物近1年股东户数变动明细见下表:根据统计,九强生物2024年3月31日至2024年6月30日,主力资金净流出1.55亿元,游资资金净流入7305.68万元,散户资金净流入8188.27万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300031537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0046","BK0028","BK0239","300406","BK0077"],"gpt_icon":0},{"id":"2461325748","title":"图解九强生物中报:第二季度单季净利润同比减0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461325748","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461325748?lang=zh_cn&edition=full","pubTime":"2024-08-23 01:30","pubTimestamp":1724347812,"startTime":"0","endTime":"0","summary":"证券之星消息,九强生物2024年中报显示,公司主营收入8.22亿元,同比上升0.66%;归母净利润2.5亿元,同比上升3.64%;扣非净利润2.48亿元,同比上升3.79%;其中2024年第二季度,公司单季度主营收入4.28亿元,同比下降3.41%;单季度归母净利润1.3亿元,同比下降0.63%;单季度扣非净利润1.27亿元,同比下降2.2%;负债率27.34%,投资收益139.84万元,财务费用2034.38万元,毛利率77.33%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300001941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"gpt_icon":0},{"id":"2461313743","title":"九强生物(300406.SZ)发布上半年业绩,净利润2.5亿元,同比增长3.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461313743","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461313743?lang=zh_cn&edition=full","pubTime":"2024-08-22 19:42","pubTimestamp":1724326944,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)发布2024年半年度报告,公司营业收入8.22亿元,同比增长0.66%;归属于上市公司股东的净利润2.5亿元,同比增长3.64%;归属于上市公司股东的扣除非经常性损益的净利润2.48亿元,同比增长3.79%;基本每股收益0.43元/股。公司一直专注体外诊断产品系统的研发,拥有一流的产品研发团队,建立起化学法、酶法(含循环酶法)、普通免疫比浊法、胶乳增强免疫比浊法、克隆酶供体酶免疫测定技术(CEDIA)、酶增强免疫测定技术(EMIT)等生化研发平台,同时也具备高水平的全液体血凝研发技术团队。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168722.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300406"],"gpt_icon":0},{"id":"2461392368","title":"九强生物最新公告:全资子公司迈新拟288.50万元收购Lumatas股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2461392368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461392368?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:41","pubTimestamp":1724323262,"startTime":"0","endTime":"0","summary":"九强生物公告,全资子公司迈新拟使用自有资金288.50万元收购林齐心先生持有的迈新美国控股子公司Lumatas的全部50万股股份。林齐心先生为公司副总经理、迈新运营副总经理,兼任Lumatas董事,属于迈新关联自然人,本次交易构成关联交易。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200034003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0028","BK0046","BK0239","300406","BK0012"],"gpt_icon":0},{"id":"2461923303","title":"九强生物最新公告:2024年上半年净利润2.50亿元 同比增长3.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2461923303","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461923303?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:39","pubTimestamp":1724323180,"startTime":"0","endTime":"0","summary":"九强生物发布2024年半年度报告,报告期内,公司实现营业收入8.22亿元,同比增长0.66%;归属于上市公司股东的净利润2.50亿元,同比增长3.64%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200034006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406"],"gpt_icon":0},{"id":"2455906423","title":"7月31日九强生物涨5.25%,农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906423?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:47","pubTimestamp":1722415651,"startTime":"0","endTime":"0","summary":"证券之星消息,7月31日九强生物涨5.25%,收盘报13.63元,换手率1.17%,成交量4.96万手,成交额6655.76万元。重仓九强生物的公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为20.52。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0012","300406","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2455491906","title":"九强生物涨5.25%,中泰证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2455491906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455491906?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:47","pubTimestamp":1722415643,"startTime":"0","endTime":"0","summary":"今日九强生物涨5.25%,收盘报13.63元。2024年5月6日,中泰证券研究员祝嘉琦,谢木青,于佳喜发布了对九强生物的研报《政策影响下业绩稳健,持续看好病理业务+国改赋能》,该研报对九强生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为78.05%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为光大证券的黎一江。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","600918"],"gpt_icon":0},{"id":"2455404146","title":"九强生物(300406)7月29日主力资金净卖出492.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455404146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455404146?lang=zh_cn&edition=full","pubTime":"2024-07-30 09:26","pubTimestamp":1722302791,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月29日收盘,九强生物报收于12.94元,下跌1.9%,换手率0.97%,成交量4.09万手,成交额5295.42万元。7月29日的资金流向数据方面,主力资金净流出492.87万元,占总成交额9.31%,游资资金净流出322.44万元,占总成交额6.09%,散户资金净流入815.31万元,占总成交额15.4%。融券方面,融券卖出6200.0股,融券偿还1.75万股,融券余量62.66万股,融券余额810.82万元。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073000014061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0046","BK0239","BK0028","BK0077","300406"],"gpt_icon":0},{"id":"2455964602","title":"九强生物(300406)29.12万股限售股将于7月30日解禁,占总股本0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455964602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455964602?lang=zh_cn&edition=full","pubTime":"2024-07-30 08:01","pubTimestamp":1722297709,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,九强生物于7月30日将有29.12万股限售股份解禁,为公司股权激励限售股份,占公司总股本0.05%。最近一年内,该股累计解禁8811.29万股,占总股本的14.97%。本次解禁后,公司还有1.65亿股限售股份,占总股本28.07%。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073000012065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","BK0077","BK0046","300406"],"gpt_icon":0},{"id":"2453070287","title":"7月23日九强生物创60日新低,农银医疗保健股票基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453070287","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453070287?lang=zh_cn&edition=full","pubTime":"2024-07-23 16:21","pubTimestamp":1721722867,"startTime":"0","endTime":"0","summary":"证券之星消息,7月23日九强生物创60日新低,收盘报13.58元,当日跌4.16%,换手率1.27%,成交量5.36万手,成交额7364.1万元。重仓九强生物的公募基金请见下表:该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为20.52。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为农银医疗保健股票。该公募基金现任基金经理为梦圆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300029739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","BK0077","300406","BK0046"],"gpt_icon":0},{"id":"2453769258","title":"九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2453769258","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453769258?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:58","pubTimestamp":1721649480,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)发布公告,截至2024年7月19日,公司本次回购股份的实施期限届满,公司累计通过股份回购专用账户以集中竞价方式实施回购公司股份482.51万股,占公司总股本的0.82%,最高成交价为19.00元/股,最低成交价为14.07元/股,支付的总金额为7897.38万元(不含交易费用)。至此,公司本次回购股份方案已实施完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300406","BK0239","BK0046","BK0028","BK0077","BK0012"],"gpt_icon":0},{"id":"2453769232","title":"【九强生物(300406.SZ)耗资7897.38万元完成回购0.82%股份】智通财经APP讯,九强生物(300406.SZ)发布公告,截至2024年7月19日,公司本次回购股份的实施期限届满,公司累计通过股份回购专用账户以集中竞价方式实施回购公司股份482.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453769232","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453769232?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:58","pubTimestamp":1721649480,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0012","BK0028","BK0239","BK0077","BK0046","300406"],"gpt_icon":0},{"id":"2452681195","title":"九强生物获得发明专利授权:“丙戊酸衍生物在免疫检测中的用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2452681195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452681195?lang=zh_cn&edition=full","pubTime":"2024-07-18 02:25","pubTimestamp":1721240701,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示九强生物新获得一项发明专利授权,专利名为“丙戊酸衍生物在免疫检测中的用途”,专利申请号为CN202211396766.7,授权日为2024年7月16日。具体而言,本申请涉及一种丙戊酸衍生物及其制备方法,以及与含有上述丙戊酸衍生物的试剂盒及其配制方法。本申请的丙戊酸检测试剂盒简便、快捷、成本低,可以在多种主流机型上进行自动化检测。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800002367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","300406","BK0046","BK0077","BK0239","BK0028"],"gpt_icon":0},{"id":"2450334339","title":"九强生物(300406)109.87万股限售股将于7月12日解禁,占总股本0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450334339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450334339?lang=zh_cn&edition=full","pubTime":"2024-07-12 08:02","pubTimestamp":1720742532,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,九强生物于7月12日将有109.87万股限售股份解禁,为公司股权激励限售股份,占公司总股本0.19%。最近一年内,该股累计解禁8720.93万股,占总股本的14.82%。本次解禁后,公司还有1.65亿股限售股份,占总股本28.07%。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200012236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300406","BK0046","BK0077","BK0028","BK0012","BK0239"],"gpt_icon":0},{"id":"2448650399","title":"【九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元】智通财经APP讯,九强生物(300406.","url":"https://stock-news.laohu8.com/highlight/detail?id=2448650399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448650399?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:38","pubTimestamp":1719823122,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0077","BK0012","300406","BK0239","BK0046","BK0028"],"gpt_icon":0},{"id":"2448280965","title":"九强生物(300406.SZ)累计回购309.5万股 耗资5264.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448280965","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448280965?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:38","pubTimestamp":1719823122,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九强生物(300406.SZ)公告,公司截至2024年6月30日以集中竞价交易方式实施回购股份合计309.5万股,占公司目前总股本的0.5260%,成交总金额为人民币5264.68万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0028","BK0239","BK0077","BK0046","300406"],"gpt_icon":0},{"id":"2448931788","title":"【中泰证券:关注Q2业绩超预期 把握医药底部资产】智通财经APP获悉,中泰证券发布研报称,展望下半年,行业基本面有望从24Q3开始改善,低基数下业绩增速有望逐季回升,政策层面创新药支持政策、医疗反腐等均有望边际向好,医药板块有望迎来一波强势反弹,建议当下提前布局底部有弹性的资产。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448931788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448931788?lang=zh_cn&edition=full","pubTime":"2024-07-01 10:36","pubTimestamp":1719801388,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","300636","LU0348784397.USD","000999","159992","BK0060","06978","BK0196","688076","BK0183","BK0010","BK0077","IE00B543WZ88.USD","300406","LU1720050803.USD","300705","BK1161","BK1515","688105","BK1574","BK0185","LU1794554557.SGD","600918","BK0188","605116","BK0012","002332","159938","LU0348783233.USD","BK0028","BK0046","LU0417516571.SGD","IE00B5MMRT66.SGD","SG9999014674.SGD","BK0239","BK0216","09926","159891","BK0276","BK0175","688336"],"gpt_icon":0},{"id":"2446169375","title":"九强生物(300406)6月27日主力资金净卖出771.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446169375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446169375?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:20","pubTimestamp":1719537651,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月27日收盘,九强生物报收于15.45元,下跌4.22%,换手率1.7%,成交量7.16万手,成交额1.12亿元。6月27日的资金流向数据方面,主力资金净流出771.68万元,占总成交额6.92%,游资资金净流入1346.17万元,占总成交额12.07%,散户资金净流出574.5万元,占总成交额5.15%。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800015770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","BK0077","BK0046","300406"],"gpt_icon":0},{"id":"2446732900","title":"九强生物(300406)6月26日主力资金净卖出322.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446732900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446732900?lang=zh_cn&edition=full","pubTime":"2024-06-27 09:12","pubTimestamp":1719450758,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月26日收盘,九强生物报收于16.13元,上涨8.18%,换手率2.75%,成交量11.61万手,成交额1.82亿元。6月26日的资金流向数据方面,主力资金净流出322.62万元,占总成交额1.77%,游资资金净流入1239.63万元,占总成交额6.81%,散户资金净流出917.01万元,占总成交额5.04%。融券方面,融券卖出37.29万股,融券偿还8.31万股,融券余量78.89万股,融券余额1272.46万元。九强生物主营业务:生化诊断、血凝检测、血型检测和肿瘤病理检测的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700013423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0239","BK0077","BK0046","300406"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-10-30","address":"北京市海淀区花园东路15号旷怡大厦5层","stockEarnings":[{"period":"1week","weight":-0.0597},{"period":"1month","weight":-0.0279},{"period":"3month","weight":-0.2406},{"period":"6month","weight":-0.3315},{"period":"1year","weight":-0.2628},{"period":"ytd","weight":-0.3169}],"companyName":"北京九强生物技术股份有限公司","boardCode":"AI0027","perCapita":"27202股","boardName":"医药制造业","registeredCapital":"58844万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 北京九强生物技术股份有限公司主营业务是生化诊断、血凝检测、血型检测和肿瘤病理诊断的研发、生产和销售。主要产品包括胱抑素C、同型半胱氨酸、胆汁酸(TBA)、载脂蛋白A1、载脂蛋白B、小而密低密度脂蛋白胆固醇、肌酸激酶同工酶(mass法)等生化诊断试剂。2023年2月22日,2022年(第29批)新认定国家企业技术中心名单及全部国家企业技术中心名单公布,公司成功入选,荣获“国家企业技术中心”认定。","serverTime":1724567255209,"listedPrice":14.32,"stockholders":"15560人(较上一季度增加18.00%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九强生物,300406,九强生物股票,九强生物股票老虎,九强生物股票老虎国际,九强生物行情,九强生物股票行情,九强生物股价,九强生物股市,九强生物股票价格,九强生物股票交易,九强生物股票购买,九强生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九强生物(300406)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九强生物(300406)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}